Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (8): 752-760.doi: 10.19982/j.issn.1000-6621.20230111
• Original Articles • Previous Articles Next Articles
Yu Zhikang1,2, Xiong Nating1,3, Wu Heming2, Du Jingjin1, Li Ling1,4()
Received:
2023-04-14
Online:
2023-08-10
Published:
2023-08-09
Contact:
Li Ling
E-mail:liling@smu.edu.cn
Supported by:
CLC Number:
Yu Zhikang, Xiong Nating, Wu Heming, Du Jingjin, Li Ling. Analysis of correlation between apolipoprotein E gene polymorphisms and lipid levels with susceptibility to pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2023, 45(8): 752-760. doi: 10.19982/j.issn.1000-6621.20230111
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20230111
特征 | 对照组(582名) | 病例组(1118例) | 统计检验值 | P值 |
---|---|---|---|---|
年龄(岁, | 60.15±11.98 | 61.97±15.34 | t=-2.690 | 0.013 |
年龄组[名/例(构成比,%)] | χ2=25.881 | <0.001 | ||
>65岁 | 190(32.6) | 508(45.4) | ||
≤65岁 | 392(67.4) | 610(54.6) | ||
性别[名/例(构成比,%)] | χ2=118.67 | <0.001 | ||
男性 | 363(62.4) | 955(85.4) | ||
女性 | 219(37.6) | 163(14.6) | ||
甘油三酯[mmol/L,M(Q1,Q3)] | 1.64(1.07,2.06) | 1.23(0.76,1.47) | U=-12.603 | <0.001 |
甘油三酯分组[名/例(构成比,%)]a | χ2=28.000 | <0.001 | ||
≤1.7mmol/L | 418(71.8) | 926(82.8) | ||
>1.7mmol/L | 164(28.2) | 192(17.2) | ||
总胆固醇(mmol/L, | 5.24±1.18 | 4.18±1.17 | t=17.605 | <0.001 |
总胆固醇分组[名/例(构成比,%)]a | χ2=43.871 | <0.001 | ||
≤5.2mmol/L | 407(69.9) | 936(83.7) | ||
>5.2mmol/L | 175(30.1) | 182(16.3) | ||
高密度脂蛋白胆固醇(mmol/L, | 1.36±0.34 | 1.14±0.38 | t=12.096 | <0.001 |
高密度脂蛋白胆固醇分组[名/例(构成比,%)]a | χ2=8.865 | 0.003 | ||
≤2.0mmol/L | 552(94.8) | 1091(97.6) | ||
>2.0mmol/L | 30(5.2) | 27(2.4) | ||
低密度脂蛋白胆固醇(mmol/L, | 2.98±0.90 | 2.36±0.82 | t=13.784 | <0.001 |
低密度脂蛋白胆固醇分组[名/例(构成比,%)]a | χ2=97.426 | <0.001 | ||
≤3.367mmol/L | 400(68.7) | 987(88.3) | ||
>3.367mmol/L | 182(31.3) | 131(11.7) | ||
载脂蛋白A1(g/L, | 1.31±0.33 | 0.94±0.32 | t=22.614 | <0.001 |
载脂蛋白A1分组[名/例(构成比,%)]a | χ2=49.011 | <0.001 | ||
≤1.16g/L | 385(66.2) | 910(81.4) | ||
>1.16g/L | 197(33.8) | 208(18.6) | ||
载脂蛋白B(g/L, | 0.97±0.29 | 0.79±0.26 | t=12.071 | <0.001 |
载脂蛋白B分组[名/例(构成比,%)]a | χ2=73.188 | <0.001 | ||
≤1.11g/L | 431(74.1) | 1005(89.9) | ||
>1.11g/L | 151(25.9) | 113(10.1) | ||
白细胞计数[×109/L,M(Q1,Q3)] | 7.49(6.10,8.70) | 9.73(6.60,11.50) | U=-9.636 | <0.001 |
中性粒细胞绝对值[×109/L,M(Q1,Q3)] | 4.41(3.30,5.20) | 7.45(4.40,9.25) | U=-16.820 | <0.001 |
淋巴细胞绝对值[×109/L,M(Q1,Q3)] | 2.34(1.80,2.7) | 1.41(0.90,1.80) | U=-23.428 | <0.001 |
单核细胞绝对值[×109/L,M(Q1,Q3)] | 0.53(0.40,0.60) | 0.70(0.50,0.90) | U=-9.274 | <0.001 |
血小板计数[×109/L,M(Q1,Q3)] | 240.31(193.00,276.00) | 272.10(190.00,334.25) | U=-4.513 | <0.001 |
红细胞计数(×1012/L, | 4.91±0.66 | 4.35±0.85 | t=14.833 | <0.001 |
血红蛋白(g/L, | 143.50±17.34 | 123.14±24.41 | t=19.739 | <0.001 |
基因 | 对照组 (582名) | 病例组 (1118例) | χ2值 | P值 | 对照组男性 (363名) | 病例组男性 (955例) | χ2值 | P值 | 对照组女性 (219名) | 病例组女性 (163例) | χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
基因型[频次(频率,%)] | ||||||||||||
ε2/ε2 | 5(0.8) | 6(0.5) | 0.619 | 0.640 | 3(0.8) | 6(0.6) | 0.152 | 0.696 | 2(0.9) | 0(0.0) | 1.496 | 0.509 |
ε2/ε3 | 49(8.4) | 146(13.1) | 8.114 | 0.004 | 30(8.3) | 116(12.1) | 4.024 | 0.045 | 19(8.7) | 30(18.4) | 7.910 | 0.005 |
ε2/ε4 | 8(1.4) | 16(1.4) | 0.009 | 0.925 | 4(1.1) | 15(1.6) | 0.407 | 0.524 | 4(1.8) | 1(0.6) | 1.064 | 0.302 |
ε3/ε3 | 418(71.8) | 767(68.6) | 1.875 | 0.171 | 259(71.3) | 650(68.1) | 1.328 | 0.249 | 159(72.6) | 117(71.8) | 0.032 | 0.859 |
ε3/ε4 | 94(16.2) | 175(15.7) | 0.71 | 0.789 | 63(17.4) | 160(16.8) | 0.068 | 0.795 | 31(14.2) | 15(9.2) | 2.164 | 0.141 |
ε4/ε4 | 8(1.4) | 8(0.7) | 1.783 | 0.182 | 4(1.1) | 8(0.8) | 0.204 | 0.652 | 4(1.8) | 0(0.0) | 3.009 | 0.139 |
等位基因[频次(频率,%)] | ||||||||||||
ε2 | 67(5.8) | 174(7.7) | 4.770 | 0.029 | 40(5.5) | 143(7.5) | 3.183 | 0.074 | 27(6.2) | 31(9.5) | 2.981 | 0.084 |
ε3 | 979(84.1) | 1855(83.0) | 0.724 | 0.395 | 611(84.2) | 1576(82.5) | 1.009 | 0.315 | 368(84.0) | 279(85.6) | 0.353 | 0.553 |
ε4 | 118(10.1) | 207(9.3) | 0.685 | 0.408 | 75(10.3) | 191(10.0) | 0.063 | 0.801 | 43(9.8) | 16(4.9) | 6.321 | 0.012 |
血脂水平 | ε2/ε2 | ε2/ε3 | ε2/ε4 | ε3/ε3 | ε3/ε4 | ε4/ε4 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
甘油三酯(mmol/L) | |||||||||||||
对照组 | 1.69(0.88,2.38) | 1.56(0.96,1.95) | 1.31(0.66,1.97) | 1.64(1.08,2.09) | 1.69(1.06,2.10) | 1.90(1.27,1.575) | |||||||
病例组 | 1.59(0.63,2.46) | 1.21(0.73,1.38) | 0.88(0.48,0.81) | 1.21(0.78,1.47) | 1.23(0.77,1.49) | 3.58(1.03,1.32) | |||||||
总胆固醇(mmol/L) | |||||||||||||
对照组 | 4.48(2.74,5.45) | 4.78±1.03 | 4.89±1.21 | 5.30±1.20 | 5.27±1.08 | 5.13(4.23,5.61) | |||||||
病例组 | 3.30(2.38,3.62) | 3.81±1.21 | 4.14±1.20 | 4.21±1.09 | 4.35±1.26 | 4.93(2.68,4.35) | |||||||
高密度脂蛋白胆固醇(mmol/L) | |||||||||||||
对照组 | 1.36±0.21 | 1.42±0.39 | 1.44±0.25 | 1.35±0.33 | 1.37±0.37 | 1.21(1.14,1.33) | |||||||
病例组 | 1.185±0.45 | 1.17±0.36 | 1.37±0.36 | 1.14±0.38 | 1.13±0.34 | 0.88(0.59,1.18) | |||||||
低密度脂蛋白胆固醇(mmol/L) | |||||||||||||
对照组 | 1.96(0.74,3.27) | 2.50±0.81 | 2.81±1.05 | 3.044±0.88 | 2.99±0.89 | 2.86(2.19,3.48) | |||||||
病例组 | 1.034(0.95,1.14) | 2.01±0.79 | 2.28±0.85 | 2.40±0.76 | 2.53±0.91 | 2.43(1.49,3.60) | |||||||
载脂蛋白A1(g/L) | |||||||||||||
对照组 | 1.20±0.23 | 1.39±0.36 | 1.34±0.18 | 1.30±0.30 | 1.33±0.41 | 1.13(1.03,1.24) | |||||||
病例组 | 1.04±0.37 | 0.96±0.32 | 1.03±0.28 | 0.94±0.33 | 0.93±0.28 | 0.85(0.49,1.06) | |||||||
载脂蛋白B(g/L) | |||||||||||||
对照组 | 0.63(0.30,1.03) | 0.83±0.28 | 0.89±0.31 | 0.98±0.28 | 0.98±0.31 | 0.93(0.81,0.97) | |||||||
病例组 | 0.43(0.33,0.55) | 0.67±0.22 | 0.76±0.25 | 0.81±0.25 | 0.83±0.26 | 0.71(0.45,0.94) | |||||||
统计检验值 | U=-0.183 | U=-3.805 | U=-1.440 | U=-10.587 | U=-5.188 | U=-1.051 | |||||||
P值a | 0.855 | <0.001 | 0.150 | <0.001 | <0.001 | 0.293 | |||||||
统计检验值 | U=-1.278 | t=5.009 | t=1.429 | t=15.420 | t=4.33 | U=-0.945 | |||||||
P值b | 0.201 | <0.001 | 0.177 | <0.001 | <0.001 | 0.345 | |||||||
统计检验值 | t=0.815 | t=3.968 | t=0.461 | t=9.707 | t=5.954 | U=-1.997 | |||||||
P值c | 0.436 | <0.001 | 0.649 | <0.001 | <0.001 | 0.046 | |||||||
统计检验值 | U=-0.730 | t=3.666 | t=1.292 | t=12.515 | t=4.043 | U=-0.946 | |||||||
P值d | 0.273 | <0.001 | 0.210 | <0.001 | <0.001 | 0.344 | |||||||
统计检验值 | t=0.864 | t=7.755 | t=2.855 | t=18.851 | t=9.567 | U=-1.787 | |||||||
P值e | 0.410 | <0.001 | 0.009 | <0.001 | <0.001 | 0.074 | |||||||
统计检验值 | U=-0.274 | t=3.491 | t=1.080 | t=10.905 | t=4.043 | U=-1.524 | |||||||
P值f | 0.784 | 0.001 | 0.292 | <0.001 | <0.001 | 0.128 |
变量 | 赋值 | 变量 | 赋值 |
---|---|---|---|
肺结核 | 非肺结核=0,肺结核=1 | 低密度脂蛋白胆固醇 | ≤3.367mmol/L=0,>3.367mmol/L=1 |
年龄 | ≤65岁=0,>65岁=1 | ||
载脂蛋白A1 | ≤1.16g/L=0,>1.16g/L=1 | ||
性别 | 女性=0,男性=1 | ||
载脂蛋白B | ≤1.11g/L=0,>1.11g/L=1 | ||
甘油三酯 | ≤1.7mmol/L=0,>1.7mmol/L=1 | ||
基因型 | ε3/ε3=0,ε2/ε2=1,ε2/ε3=2,ε2/ε4=3, ε3/ε4=4, ε4/ε4=5 | ||
总胆固醇 | ≤5.2mmol/L=0,>5.2mmol/L=1 | ||
高密度脂蛋白胆固醇 | ≤2.0mmol/L=0,>2.0mmol/L=1 | 等位基因 | ε3=0,ε2=1,ε4=2 |
变量 | β值 | s | Wald χ2值 | P值 | OR(95%CI)值 |
---|---|---|---|---|---|
年龄>65岁 | 0.478 | 0.129 | 13.703 | 0.001 | 1.613(1.252~2.077) |
男性 | 0.698 | 0.146 | 22.831 | 0.001 | 2.009(1.509~2.674) |
甘油三酯>1.7mmol/L | -0.945 | 0.145 | 42.749 | 0.001 | 0.389(0.293~0.516) |
总胆固醇>5.2mmol/L | -0.781 | 0.191 | 16.752 | 0.001 | 0.458(0.315~0.666) |
高密度脂蛋白胆固醇>2.0mmol/L | 0.67 | 0.309 | 4.713 | 0.030 | 1.955(1.067~3.581) |
低密度脂蛋白胆固>3.367mmol/L | -0.141 | 0.235 | 0.36 | 0.548 | 0.869(0.548~1.376) |
载脂蛋白A1>1.16g/L | -1.952 | 0.134 | 213.75 | 0.001 | 0.142(0.109~0.184) |
载脂蛋白B>1.11g/L | 0.093 | 0.228 | 0.167 | 0.683 | 1.098(0.703~1.715) |
载脂蛋白E基因型 | |||||
ε2/ε2 | -0.468 | 0.677 | 0.478 | 0.489 | 0.626(0.166~2.360) |
ε2/ε3 | 0.567 | 0.210 | 7.266 | 0.007 | 1.763(1.167~2.661) |
ε2/ε4 | 0.121 | 0.539 | 0.050 | 0.823 | 1.128(0.392~3.245) |
ε3/ε4 | -0.035 | 0.170 | 0.043 | 0.835 | 0.965(0.692~1.346) |
ε4/ε4 | -0.489 | 0.600 | 0.666 | 0.414 | 0.613(0.189~1.986) |
等位基因 | |||||
ε2 | 0.489 | 0.202 | 5.859 | 0.015 | 1.630(1.097~2.421) |
ε4 | -0.066 | 0.165 | 0.159 | 0.691 | 0.937(0.678~1.293) |
[1] |
Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol, 2017, 17(11): 691-702. doi:10.1038/nri.2017.69.
doi: 10.1038/nri.2017.69 pmid: 28736436 |
[2] |
Cai L, Li Z, Guan X, et al. The Research Progress of Host Genes and Tuberculosis Susceptibility. Oxid Med Cell Longev, 2019, 2019: 9273056. doi:10.1155/2019/9273056.
doi: 10.1155/2019/9273056 |
[3] |
Maurya RK, Bharti S, Krishnan MY. Triacylglycerols: Fuelling the Hibernating Mycobacterium tuberculosis. Front Cell Infect Microbiol, 2018, 8: 450. doi:10.3389/fcimb.2018.00450.
doi: 10.3389/fcimb.2018.00450 URL |
[4] |
Daniel J, Maamar H, Deb C, et al. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog, 2011, 7(6): e1002093. doi:10.1371/journal.ppat.1002093.
doi: 10.1371/journal.ppat.1002093 URL |
[5] | Carlos P, Vargas MH, Torrescruz A, et al. La hipocolesterolemia: un hallazgo frecuente que se asocia a la tuberculosis. Revista Del Instituto Nacional De Enfermedades Respiratorias, 2002, 15(1): 7-11. |
[6] |
Soh AZ, Chee CB, Wang YT, et al. Dietary Cholesterol Increases the Risk whereas PUFAs Reduce the Risk of Active Tuberculosis in Singapore Chinese. J Nutr, 2016, 146(5): 1093-1100. doi:10.3945/jn.115.228049.
doi: 10.3945/jn.115.228049 pmid: 27075903 |
[7] |
Martens GW, Arikan MC, Lee J, et al. Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun, 2008, 76(8): 3464-3472. doi:10.1128/IAI.00037-08.
doi: 10.1128/IAI.00037-08 pmid: 18505807 |
[8] |
Deniz O, Gumus S, Yaman H, et al. Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis. Clin Biochem, 2007, 40(3/4): 162-166. doi:10.1016/j.clinbiochem.2006.10.015.
doi: 10.1016/j.clinbiochem.2006.10.015 URL |
[9] |
Lumsden AL, Mulugeta A, Zhou A, et al. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine, 2020, 59: 102954. doi:10.1016/j.ebiom.2020.102954.
doi: 10.1016/j.ebiom.2020.102954 |
[10] |
Kuo CL, Pilling LC, Atkins JL, et al. ApoE e4e 4 Genotype and Mortality With COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci, 2020, 75(9): 1801-1803. doi:10.1093/gerona/glaa169.
doi: 10.1093/gerona/glaa169 URL |
[11] |
Wang D, Zhang DF, Li GD, et al. A pleiotropic effect of the APOE gene: association of APOE polymorphisms with multibacillary leprosy in Han Chinese from Southwest China. Br J Dermatol, 2018, 178(4): 931-939. doi:10.1111/bjd.16020.
doi: 10.1111/bjd.16020 pmid: 28977675 |
[12] |
Kuhlmann I, Minihane AM, Huebbe P, et al. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis, 2010, 9: 8. doi:10.1186/1476-511X-9-8.
doi: 10.1186/1476-511X-9-8 pmid: 20109174 |
[13] |
Martin GM. APOE alleles and lipophylic pathogens. Neurobiol Aging, 1999, 20(4):441-443. doi:10.1016/s0197-4580(99)00078-0.
doi: 10.1016/s0197-4580(99)00078-0 pmid: 10604437 |
[14] |
Wozniak MA, Maude RJ, Innes JA, et al. Apolipoprotein E-epsilon2 confers risk of pulmonary tuberculosis in women from the Indian subcontinent-a preliminary study. J Infect, 2009, 59(3): 219-222. doi:10.1016/j.jinf.2009.07.003.
doi: 10.1016/j.jinf.2009.07.003 URL |
[15] |
Rao H, Wu H, Yu Z, et al. APOE Genetic Polymorphism rs 7412 T/T Genotype May Be a Risk Factor for Essential Hypertension among Hakka People in Southern China. Int J Hypertens, 2022, 2022: 8145896. doi:10.1155/2022/814589.
doi: 10.1155/2022/814589 |
[16] |
Yao X, Gordon EM, Figueroa DM, et al. Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung Disease. Am J Respir Cell Mol Biol, 2016, 55(2): 159-169. doi:10.1165/rcmb.2016-0060TR.
doi: 10.1165/rcmb.2016-0060TR URL |
[17] |
van den Elzen P, Garg S, León L, et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature, 2005, 437(7060): 906-910. doi:10.1038/nature04001.
doi: 10.1038/nature04001 |
[18] |
Figueroa DM, Gordon EM, Yao X, et al. Apolipoproteins as context-dependent regulators of lung inflammation. Mechanisms and Manifestations of Obesity in Lung Disease, 2019:301-326. doi:10.1016/B978-0-12-813553-2.00013-0.
doi: 10.1016/B978-0-12-813553-2.00013-0 |
[19] |
Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E-A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features. Comput Struct Biotechnol J, 2017, 15: 359-365. doi:10.1016/j.csbj.2017.05.003.
doi: 10.1016/j.csbj.2017.05.003 URL |
[20] |
Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet, 2000, 1:507-537. doi:10.1146/annurev.genom.1.1.507.
doi: 10.1146/annurev.genom.1.1.507 pmid: 11701639 |
[21] |
Laval T, Chaumont L, Demangel C. Not too fat to fight: The emerging role of macrophage fatty acid metabolism in immunity to Mycobacterium tuberculosis. Immunol Rev, 2021, 301(1): 84-97. doi:10.1111/imr.12952.
doi: 10.1111/imr.12952 URL |
[22] |
Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation, 2012, 125(15): 1905-1919. doi:10.1161/CIRCULATIONAHA.111.066589.
doi: 10.1161/CIRCULATIONAHA.111.066589 pmid: 22508840 |
[23] |
Chidambaram V, Zhou L, Ruelas Castillo J, et al. Higher Serum Cholesterol Levels Are Associated With Reduced Systemic Inflammation and Mortality During Tuberculosis Treatment Independent of Body Mass Index. Front Cardiovasc Med, 2021, 8: 696517. doi:10.3389/fcvm.2021.696517.
doi: 10.3389/fcvm.2021.696517 URL |
[24] |
Wang J, Yin Y, Wang X, et al. Ratio of monocytes to lymphocytes in peripheral blood in patients diagnosed with active tuberculosis. Braz J Infect Dis, 2015, 19(2):125-131. doi:10.1016/j.bjid.2014.10.008.
doi: 10.1016/j.bjid.2014.10.008 pmid: 25529365 |
[25] |
Farivar TN, Moud BS, Sargazi M, et al. Apolipoprotein E Polymorphism in Tuberculosis Patients. Journal of Applied Sciences, 2008, 8: 719-722. doi:10.3923/jas.2008.719.722.
doi: 10.3923/jas.2008.719.722 URL |
[26] |
Caruso C, Ligotti ME, Accardi G, et al. How Important Are Genes to Achieve Longevity? Int J Mol Sci, 2022, 23(10): 5635. doi:10.3390/ijms23105635.
doi: 10.3390/ijms23105635 URL |
[27] |
Kulminski AM, Shu L, Loika Y, et al. APOE region molecular signatures of Alzheimer’s disease across races/ethnicities. Neurobiol Aging, 2020, 87:141.e1-141.e8. doi:10.1016/j.neurobiolaging.2019.11.007.
doi: 10.1016/j.neurobiolaging.2019.11.007 |
[28] |
Andersen CJ. Impact of Dietary Cholesterol on the Pathophysiology of Infectious and Autoimmune Disease. Nutrients, 2018, 10(6): 764. doi:10.3390/nu10060764.
doi: 10.3390/nu10060764 URL |
[29] |
Garcia AR, Finch C, Gatz M, et al. APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population. Elife, 2021, 10: e68231. doi:10.7554/eLife.68231.
doi: 10.7554/eLife.68231 |
[1] | Huang Hairong. Interpretation of the World Health Organization's Use of targeted next-generation sequencing to detect drug-resistant tuberculosis Rapid communication, 2023 [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 921-924. |
[2] | Yu Meiling, Zhang Chenchen, Wei Wenjing, Zhao Yuchuan, Zhuo Wenji, Zheng Lei. Study on high-concentration p-aminosalicylic acid resistant Mycobacterium tuberculosis induced in vitro and the mutation sites [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 60-66. |
[3] | SUN Qing, LIAO Xin-lei, WANG Chen-qian, JIANG Guang-lu, DONG Ling-ling, WANG Fen, ZHAO Li-ping, HUANG Hai-rong, WANG Gui-rong. Characterization of rifampin resistance determining region mutations in tuberculosis patients with GeneXpert MTB/RIF positive RNA polymerase β subunit gene mutation [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 349-353. |
[4] | Peng Lijun, Fang Tingting, Cai Long. Development and challenges of Mycobacterium tuberculosis cfDNA in the diagnosis of tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(10): 1091-1095. |
[5] | ZHOU Ting-ting, ZHENG Xiao-man, OUYANG Jing, LU Yan-qiu, CHEN Yao-kai. Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 102-105. |
[6] | WANG Lu, XUE Zhong-tan, WANG Yu-feng, SHANG Yuan-yuan, REN Wei-cong, YAO Cong, GAO Fei, PANG Yu. A study of dynamic monitoring of drug sensitivity of Mycobacterium tuberculosis to bedaquiline and the mechanism of drug resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 482-486. |
[7] | CAO Xin-yu, XUE Miao, WEN Yan, LIU Li. Research progress on susceptibility genes of anti-tuberculous drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 190-193. |
[8] | LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488. |
[9] | SONG Ke-yu, ZHANG Qin, WANG Wen-jing, SHI Rui, WU Xu-ping. Analysis of drug-resistance of 1719 mycobacterium strains in Nanjing from 2017 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1214-1220. |
[10] | ZHANG Man-e,HUANG Wen-bin,LU Zhi-hua,ZHANG Hong-bin. Study on resistance to rifampicin and isoniazid in 411 cases of pulmonary tuberculosis in Longyan City, Fujian Province [J]. Chinese Journal of Antituberculosis, 2020, 42(1): 54-59. |
[11] | Guang-gui DING,Xing HE,Juan LIANG,Ya-ya LIU,Min OU,Jian LU,Guo-liang ZHANG. Effect of miR-20a-5p on the expression of apoptosis-related genes in Mycobacterium tuberculosis-infected human macrophages [J]. Chinese Journal of Antituberculosis, 2019, 41(7): 747-753. |
[12] | Zhao-gang SUN,Hong-jing ZHANG,Zi-hui LI,Qi SUN,Lin-na LYU,Li-ping PAN,Gilbert Sandy,Zong-de ZHANG,Shao-fa XU,Xia James. Design of a next generation microsequencing gene microarray and preliminary study of its effect on drug resistance detection [J]. Chinese Journal of Antituberculosis, 2019, 41(6): 609-615. |
[13] | Yan-hua SONG,Gui-rong WANG,Feng-min HUO,Rong-mei LIU,Meng-qiu GAO,Qi. LI. Correlation analysis between inhA gene mutation and protionamide-resistance in multidrug resistance and extensively drug-resistant Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2018, 40(8): 821-824. |
[14] | Da-mian ZHU,Dai-yu HU,Jie LIU,Yu PANG,Ming LUO,Jing SHEN,Lin. CHEN. Analysis of mutation in pyrazinamide-resistance gene among the multidrug-resistant Mycobacterium tuberculosis strains isolated from Chongqing municipality [J]. Chinese Journal of Antituberculosis, 2018, 40(2): 177-182. |
[15] | SUN Lin, SHEN A-dong. Application of metabonomic technology in tuberculosis [J]. Chinese Journal of Antituberculosis, 2016, 38(3): 175-179. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||